FDA Approves ResolutionMD for Diagnosis on Mobile Devices
Calgary Scientific’s ResolutionMD received FDA clearance for diagnosis on mobile devices for most imaging modalities.
ResolutionMD, an enterprise image-viewing solution, has been approved by the U.S. Food and Drug Administration (FDA) for diagnosis on mobile devices for most imaging modalities.
Calgary Scientific, Inc., the company behind ResolutionMD, worked with multiple radiologists worldwide to clinically validate the solution before submitting it to the FDA. ResolutionMD allows doctors to securely view patient images and reports from a variety of computers and mobile devices. It also offers the ability to collaborate with other practitioners and diagnose from any location.
The mobile medical diagnosis software of ResolutionMD can be integrated into any EMR and plugged into existing distributed storage systems. The FDA’s safety and effectiveness review found ResolutionMD to be substantially equivalent to PACS or dedicated diagnostic workstations.
ResolutionMD has been cleared to diagnose modalities such as CR, DR, radio-fluoroscopy, angiography, ultrasound, nuclear medicine, endoscopy and ophthalmology.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
New Analysis Forecasts Substantial Cost Savings with the Use of Photon Counting CT for CCTA
March 8th 2025The use of ultra-high-resolution photon-counting CT in the evaluation of stable chest pain may significantly reduce follow-up tests and invasive coronary angiography (ICA) procedures, possibly resulting in millions in health-care cost savings, according to a cost-effectiveness analysis presented recently at the European Congress of Radiology.
